Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study

Ali Taher, Amal El-Beshlawy, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalEuropean Journal of Haematology
Volume82
Issue number6
DOIs
Publication statusPublished - Jun 2009

    Fingerprint

Keywords

  • β-thalassaemia
  • Deferasirox
  • Iron chelation
  • Transfusional iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Taher, A., El-Beshlawy, A., Elalfy, M. S., Al Zir, K., Daar, S., Habr, D., Kriemler-Krahn, U., Hmissi, A., & Al Jefri, A. (2009). Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study. European Journal of Haematology, 82(6), 458-465. https://doi.org/10.1111/j.1600-0609.2009.01228.x